ライフサイエンスコーパス: relapsing

1 w to accurately determine which patients are relapsing.

2 ecting species as Trypanosoma evansi.Despite relapsing 6 weeks after completing amphotericin B therap

3 neuromyelitis optica spectrum disorders and relapsing acute disseminated encephalomyelitis, and char

4 hosphamide in patients with multiple myeloma relapsing after a first ASCT.

5 Eligible patients with multiple myeloma relapsing after a previous ASCT were re-induced with int

6 ivolumab as a single agent in 20 HL patients relapsing after allo-HCT.

7 o the heterogeneous genetic landscape of CLL relapsing after FCR treatment and highlight a novel mech

8 s has been made in the long-term survival of relapsing AML patients, urging for the development of no

9 that cortical reorganization occurs in both relapsing and chronic phases of EAE with increased activ

10 rmed before disease induction and during the relapsing and chronic phases of EAE.

11 Neuroinflammation persisted in the relapsing and chronic phases, with dendritic spine densi

12 Ulcerative colitis (UC) is a chronic, relapsing and debilitating idiopathic inflammation, with

13 es and compares the pathological findings in relapsing and progressive multiple sclerosis patients.

14 al states of microglia/macrophages in acute, relapsing and progressive multiple sclerosis.

15 able, and the disease can be classified into relapsing and progressive phases.

16 isorder characterized by clonal diversity, a relapsing and remitting course, and in its aggressive fo

17 t is likely that they have a role in chronic relapsing and remitting diseases of both barrier and non

18 ly related species responsible for a chronic relapsing and remitting infection in PAD patients in the

19 s of metabolic stress that model the initial relapsing and subsequent progressive phases of MS.

20 is a frequent skin disease characterized by relapsing appearance of pruritic hives.

21 orders of the inflammasome may contribute to relapsing attacks; and 4) therapies that target the infl

22 utoantibody-associated vasculitis, a chronic relapsing autoimmune inflammatory disease associated wit

23 body has been identified as a biomarker of a relapsing autoimmune meningoencephalomyelitis that is im

24 reatment of an immunosuppressed patient with relapsing babesiosis.

25 he bladder, this treatment failed to prevent relapsing bacteriuria.

26 negative emotional state leading to chronic relapsing behavior.

27 rinary tract and prevents the development of relapsing bouts of bacteriuria.

28 Cigarette smoking is a chronic relapsing brain disorder, and remains a premier cause of

29 otein 9 (CARD9) deficiency in a patient with relapsing C. albicans meningoencephalitis.

30 y and physical disability in AP4-Ab negative relapsing cases.

31 (FFT) in 5 patients with symptomatic chronic-relapsing CDI at the Department of Internal Medicine I a

32 adult-dominant unselected cohort with mainly relapsing central nervous system (CNS) inflammatory dise

33 Considering its chronic relapsing character, accurate and timely diagnosis of an

34 icrobiota transplantation (FMT) utilized for relapsing Clostridium difficile colitis successfully era

35 dult-predominant unselected cohort of mainly relapsing CNS inflammatory diseases, we confirmed that N

36 disease and ulcerative colitis, are chronic relapsing conditions that affect a growing number of chi

37 Patients with a relapsing course (median number of relapses = 1, range:

38 rom splenic artery pseudoaneurysm can have a relapsing course providing false negative results of end

39 A relapsing course suggested an increased risk for visual

40 adult life, CMH followed a dynamic remitting-relapsing course.

41 In addition, further relapsing demyelinating episodes associated with MOG ant

42 munocompetent, and 65% were symptomatic with relapsing diarrhea, indicating a distinct clinical manif

43 ered the risk of visual loss, independent of relapsing disease course (OR = 0.79; 95% CI, 0.66-0.94,

44 primary progressive) or can be preceded by a relapsing disease course (secondary progressive).

45 PPMS were compared to those that developed a relapsing disease course from onset (clinically isolated

46 poor prognostic factors, and complicated or relapsing disease course were associated with future rel

47 Relapsing disease is common among immunocompromised and

48 opic polyangiitis), or new diagnosis (versus relapsing disease) at entry.

49 entify parasite variants that associate with relapsing disease, including amino acid substitutions in

50 atient years in two patients with active and relapsing disease, then in one of these patients after l

51 and tolerable alternatives for this multiply-relapsing disease.

52 ith multiple sclerosis, improving control of relapsing disease.

53 sease, whereas multiple injections induced a relapsing disease.

54 STATEMENT Alcohol use disorder is a chronic relapsing disorder that is associated with compulsive al

55 ion of CXCL11-Ig during the first episode of relapsing EAE in SJL/J mice not only led to rapid remiss

56 etic sulfatide can treat ongoing chronic and relapsing EAE in SJL/J mice.

57 limus is approved for tamoxifen-resistant or relapsing estrogen receptor-positive breast cancer, thes

58 antigen-specific hypersensitivity reactions, relapsing experimental autoimmune encephalomyelitis, and

59 spinal cord of mice subjected to chronic or relapsing experimental autoimmune encephalomyelitis.

60 as a human pathogen causing hard tick-borne relapsing fever (HTBRF) across the Northern Hemisphere.

61 aracterize surface proteins expressed by the relapsing fever (RF) agent Borrelia hermsii in the blood

62 Tick-borne relapsing fever (RF) borreliosis is a neglected disease

63 th during the cell cycle is also observed in relapsing fever Borrelia.

64 Borrelia miyamotoi is a relapsing fever spirochete in Ixodes ticks that has been

65 systems for the genetic manipulation of the relapsing fever spirochetes.

66 the Western Front reported on a soldier with relapsing fever, headache, dizziness, lumbago, and shin

67 Agents that cause Lyme disease, relapsing fever, leptospirosis, and syphilis belong to t

68 The Lyme disease (Borrelia burgdorferi) and relapsing-fever (Borrelia hispanica) agents have distinc

69 e lymphoblastic leukemia (ALL) persisting or relapsing following bone marrow transplantation (BMT) ha

70 ple and increasingly effective therapies for relapsing forms of multiple sclerosis (MS), disease-free

71 and Drug Administration for the treatment of relapsing forms of multiple sclerosis (MS).

72 decades have revolutionized the treatment of relapsing forms of multiple sclerosis.

73 Prostate cancer relapsing from antiandrogen therapies can exhibit varian

74 g therapy was associated with risk, patients relapsing from very good partial response (VGPR) or bett

75 st line may be those patients who are either relapsing from VGPR or better (dFLC at diagnosis was >5

76 and in a model derived from an AFP-negative relapsing HB.

77 Thirty-three patients with a unilateral and relapsing herpes simplex keratitis (HSK group) that was

78 iescent phase of the disease, unilateral and relapsing HSK significantly impairs the QoL of patients

79 iescent phase of the disease, unilateral and relapsing HSK significantly impairs the QoL of patients

80 nce in the number of hospitalisations due to relapsing IBD during follow-up.

81 The mouse DNBS model of relapsing IBD was used to compare the protective effects

82 bowel diseases (IBDs) are defined as chronic relapsing immune-mediated disorders of the gastrointesti

83 We performed whole-exome sequencing on 10 relapsing individuals and 11 controls from 5 nuclear fam

84 en, responsible for a variety of chronic and relapsing infections such as osteomyelitis, endocarditis

85 ariants (SCVs) are implicated in chronic and relapsing infections that are difficult to diagnose and

86 athogenesis of Crohn disease (CD), a chronic relapsing inflammatory disorder of the intestinal tract.

87 pathogenesis of atopic dermatitis, a chronic relapsing inflammatory skin disorder characterized by un

88 Inflammatory bowel disease causes chronic, relapsing intestinal inflammation that can lead to the d

89 yzed biopsy samples from paired baseline and relapsing lesions in four patients with metastatic melan

90 to control and eliminate this major cause of relapsing malaria.

91 facilitate the discovery of drugs targeting relapsing malaria.

92 Among novel drugs used to treat relapsing MCL patients, ibrutinib, an oral inhibitor of

93 Patients with relapsing MS (RMS) had smaller thoracic cord GM areas th

94 generation and more rapid remyelination make relapsing MS more resilient than the progressive subtype

95 In relapsing MS patients, plasma levels of CXCL5, another E

96 and 18.1% (95% CI = 13.5-22.5%) evolved from relapsing MS to secondary progressive MS (SPMS).

97 ng monoclonal antibody, effectively inhibits relapsing multiple sclerosis (MS) but is associated with

98 tal role in mediating the clinical course of relapsing multiple sclerosis (MS).

99 rate (DMF) is indicated for the treatment of relapsing multiple sclerosis and may exert therapeutic e

100 DMT who were enrolled in the UK RSS who had relapsing multiple sclerosis at baseline and had at leas

101 ger clinical trials in optic neuritis and in relapsing multiple sclerosis is warranted.

102 randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocre

103 and the USA, patients aged 18-60 years with relapsing multiple sclerosis were randomly assigned via

104 Patients with relapsing multiple sclerosis were recruited from 55 acad

105 , crossover trial (ReBUILD) in patients with relapsing multiple sclerosis with chronic demyelinating

106 Among patients with relapsing multiple sclerosis, ocrelizumab was associated

107 ced MRI lesion activity in participants with relapsing multiple sclerosis, with a favourable safety p

108 beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing

109 approved for the treatment of patients with relapsing multiple sclerosis.

110 receptor modulator ozanimod in patients with relapsing multiple sclerosis.

111 ndrocyte DNA was identified in patients with relapsing multiple sclerosis; neuronal/glial DNA was ide

112 The widespread distribution and relapsing nature of Plasmodium vivax infection present m

113 ude a separate category of complex inherited relapsing neuropathy syndromes, some of which may mimic

114 lated disability milestones are identical to relapsing-onset disease.

115 ty endpoints was compared with patients with relapsing-onset MS (ROMS) using survival analysis, and C

116 bcortical gray matter fraction in women with relapsing-onset MS (standard beta = -1.20 x 10-1; P = 1.

117 A total of 619 (95.8%) had relapsing-onset MS and 27 (4.2%) had progressive-onset M

118 significant difference was observed between relapsing-onset MS and primary progressive MS.

119 ith MS were approximately 9 years later than relapsing-onset patients (p=1.40x10(-265)).

120 rial, we randomly assigned participants with relapsing or refractory eosinophilic granulomatosis with

121 -modifying therapy approved for treatment of relapsing or relapsing-remitting multiple sclerosis.

122 ion in 28 pediatric patients with frequently relapsing or steroid-dependent nephrotic syndrome.

123 pe of failure (BCG unresponsive, refractory, relapsing, or intolerant) should be clearly defined to m

124 ver schizonts and dormant hypnozoites of the relapsing parasite Plasmodium cynomolgi.

125 All relapsing patients had choroidal tumors and 15 presented

126 ference at baseline between nonrelapsing and relapsing patients in several clinical parameters and ce

127 toward advanced phase CML occurred, and all relapsing patients regained MMR and MR4.5 after restarti

128 Median survival of relapsing patients was 59 months.

129 Fifty relapsing patients with multiple sclerosis (MS) who had

130 reatment option for both treatment-naive and relapsing patients.

131 Identification of new treatments for relapsing pediatric cancer is an unmet clinical need and

132 The undetectable hypnozoite reservoir for relapsing Plasmodium vivax and P. ovale malarias present

133 In 5 prospectively diagnosed patients with relapsing post-herpes simplex encephalitis (HSE), N-meth

134 ce of hypnozoite activation as the source of relapsing primate malaria can be looked for.

135 Patients with relapsing/refractory CDI were randomized to receive an i

136 e with a clinically isolated syndrome (CIS), relapsing remitting (RR) and secondary progressive (SP)

137 Among 806 patients with relapsing remitting (RR) onset MS from the London Ontari

138 Forty-three patients with relapsing remitting and 28 with secondary progressive mu

139 ith distance from the ventricles in both the relapsing remitting and secondary progressive multiple s

140 secondary progressive disease and 14 with a relapsing remitting disease course) underwent T1- and T2

141 Because atopic dermatitis (AD) is a relapsing remitting disease, assessing long-term control

142 d in MS by comparing the fecal microbiota in relapsing remitting MS (RRMS) (n = 31) patients to that

143 ith secondary progressive MS [SPMS], 27 with relapsing remitting MS [RRMS]) and 30 healthy volunteers

144 ntegrity of processing of structural RNAs in relapsing remitting multiple sclerosis (RRMS) and other

145 rom the cerebrospinal fluid of patients with relapsing remitting multiple sclerosis (RRMS) have highe

146 progressive multiple sclerosis compared with relapsing remitting multiple sclerosis group, and these

147 Thirty-nine patients with relapsing remitting multiple sclerosis, at high risk of

148 s, and more so in secondary progressive than relapsing remitting multiple sclerosis, tissue structura

149 t approved oral therapy for the treatment of relapsing remitting multiple sclerosis.

150 lications for the diagnosis and treatment of relapsing remitting multiple sclerosis.

151 ins the most widely prescribed treatment for relapsing remitting multiple sclerosis.

152 ormalities between secondary progressive and relapsing remitting multiple sclerosis.

153 ation reflected behaviour in the subgroup of relapsing remitting patients (rho = 0.74, P = 0.008).

154 ctions of white matter lesion enlargement in relapsing remitting patients and is associated with grea

155 rrently being evaluated for the treatment of relapsing, remitting, and primary progressive multiple s

156 and efficacy of amiselimod in patients with relapsing- remitting multiple sclerosis.

157 6 +/- 1.39 versus 49.13 +/- 1.19, P < 0.01), relapsing-remitting (48.86 +/- 2.89 versus 47.44 +/- 2.7

158 We investigated this in people with relapsing-remitting (RR) and secondary progressive (SP)

159 raphically matched normal controls (NC), and relapsing-remitting (RR) MS patients, also matched with

160 copy, we analysed the lipoprotein profile of relapsing-remitting (RR) MS patients, progressive MS pat

161 Most patients with relapsing-remitting (RR) multiple sclerosis (MS) who rec

162 d degenerating brain and spinal cord in both relapsing-remitting and progressive forms of MS and may

163 Individuals suffering from relapsing-remitting and secondary progressive MS had sig

164 This case of relapsing-remitting AVWS demonstrates the use of VWFpp:A

165 fected with M. amphoriforme manifesting as a relapsing-remitting bacterial load, interspersed by peri

166 em traditionally characterized by an initial relapsing-remitting clinical course and focal inflammato

167 The case is presented due to the relapsing-remitting clinical course of the disease that

168 Despite varying prior severity of relapsing-remitting course, all participants experienced

169 Patients with MS with relapsing-remitting disease course or SP were included.

170 ression was more common in younger patients, relapsing-remitting disease course, and after a smaller

171 y of myelin-reactive CD4 T cells that elicit relapsing-remitting disease have not been quantified.

172 d by a global increasing incidence driven by relapsing-remitting disease in females.

173 t decisions are based on what is known about relapsing-remitting disease remains unclear.

174 ocyte ratio was observed in MS patients with relapsing-remitting disease.

175 nantly of younger patients and patients with relapsing-remitting disease.

176 g the first relapse in a SJL animal model of relapsing-remitting EAE abrogated clinical disease, infl

177 of Del-1-Fc ameliorated clinical relapse in relapsing-remitting EAE.

178 preclinically, could suppress progression of relapsing-remitting experimental autoimmune encephalomye

179 ition of system Xc(-) attenuates chronic and relapsing-remitting experimental autoimmune encephalomye

180 Moreover, guanabenz ameliorates relapse in relapsing-remitting experimental autoimmune encephalomye

181 d progressive, as well as PLP138-151-induced relapsing-remitting experimental autoimmune encephalomye

182 d on the 2010 McDonald criteria (34 with the relapsing-remitting form, 2 with clinically isolated syn

183 ges were significant in both progressive and relapsing-remitting forms of the disease and correlated

184 , whereas the classifier that differentiates relapsing-remitting from progressive MS achieved a valid

185 models of autoimmunity, type 1 diabetes and relapsing-remitting immune-mediated demyelination.

186 Multiple sclerosis (MS) is a chronic relapsing-remitting inflammatory disease of the central

187 males with progressive disease compared with relapsing-remitting males (RRMS) and female MS subjects,

188 ectroscopic imaging data in 46 patients with relapsing-remitting MS (median disease duration, 0.8 yea

189 Case series of patients with relapsing-remitting MS (n = 123) or secondary-progressiv

190 Patients with active relapsing-remitting MS (n=20) and healthy controls (n=8)

191 Patients with relapsing-remitting MS (RRMS) or clinically isolated syn

192 secondary-progressive MS (SPMS) patients, 12 relapsing-remitting MS (RRMS) patients, and 14 matched h

193 majority of plaques in acute monophasic and relapsing-remitting MS (RRMS) were active.

194 odic relapses followed by remissions, called relapsing-remitting MS (RRMS).

195 inically isolated syndrome (CIS) and 69 with relapsing-remitting MS (RRMS; mean age: CIS: 31.4 +/- 9.

196 in progressive MS (r = 0.67; p < 0.001) than relapsing-remitting MS (RRMS; r = 0.33; p = 0.007).

197 atic carriers of HTLV-1 (AC), 47 HAM/TSP, 74 relapsing-remitting MS [RRMS], 17 secondary progressive

198 In a prospective study, 326 patients with relapsing-remitting MS and 163 patients with progressive

199 Twenty-five patients with relapsing-remitting MS and 20 healthy control subjects u

200 Forty-eight patients with relapsing-remitting MS and 24 control subjects underwent

201 Fifty-seven consecutive patients with relapsing-remitting MS and 30 healthy, age-matched contr

202 Twenty-six patients with relapsing-remitting MS and 32 healthy control subjects f

203 One hundred patients with relapsing-remitting MS and 50 healthy controls.

204 diagnosis of clinically isolated syndrome or relapsing-remitting MS and a minimum of 7 years of prosp

205 sability Status Scale score of 3.5 to 6.5 or relapsing-remitting MS and an Expanded Disability Status

206 nce images were acquired from 133 women with relapsing-remitting MS and analyzed using voxel-based mo

207 eters to explain IPS and EF in patients with relapsing-remitting MS and confirms the central role of

208 mean age 33.4 yrs) with clinically definite, relapsing-remitting MS and mild disability (EDSS - Expan

209 written informed consent, six patients with relapsing-remitting MS and six healthy control subjects

210 Whereas results were similar for relapsing-remitting MS cases (RRMS), those developing pr

211 onal cohort study included 312 patients with relapsing-remitting MS in 2 independent cohorts (72 pati

212 eased in patients with clinically definitive relapsing-remitting MS in comparison with healthy contro

213 t study, 14 healthy control participants, 18 relapsing-remitting MS multiple sclerosis ( RRMS relaxin

214 Ten relapsing-remitting MS patients were studied using the T

215 Relapsing-remitting MS patients who developed PML under

216 Data on 201 pregnant women with relapsing-remitting MS were collected prospectively from

217 the phase 2 studies) and diagnosed as having relapsing-remitting MS were eligible to participate in t

218 Participants included patients with relapsing-remitting MS who were switching therapy to fin

219 creased in peripheral blood of patients with relapsing-remitting MS with a high disease score.

220 onset (clinically isolated syndrome [CIS] or relapsing-remitting MS) and were also compared to two ot

221 Among patients with relapsing-remitting MS, nonmyeloablative hematopoietic s

222 play a role in the inflammatory response in relapsing-remitting MS.

223 n at the same doses shown to be effective in relapsing-remitting MS.

224 d with worsening of disease in patients with relapsing-remitting MS.

225 174 relapsing-remitting MS/CIS patients were included in thi

226 3 years disease duration), 18 subjects with relapsing-remitting multiple sclerosis (>/= 4 years dise

227 Patients with relapsing-remitting multiple sclerosis (age 18-65 years,

228 rimary and secondary-progressive compared to relapsing-remitting multiple sclerosis (coefficients = -

229 atients with clinically isolated syndrome or relapsing-remitting multiple sclerosis (Expanded Disabil

230 Hematopoietic Cell Transplantation for Relapsing-Remitting Multiple Sclerosis (HALT-MS) is an o

231 The use of natalizumab for highly active relapsing-remitting multiple sclerosis (MS) is influence

232 Unexpectedly, progressive and relapsing-remitting multiple sclerosis (MS) patients hav

233 No current therapy for relapsing-remitting multiple sclerosis (MS) results in s

234 ical and MRI activity in adult patients with relapsing-remitting multiple sclerosis (MS).

235 acetate therapy on B cells in patients with relapsing-remitting multiple sclerosis (MS).

236 ts with clinically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progr

237 ger-type lesion' in an independent cohort of relapsing-remitting multiple sclerosis (RRMS) and AQP4-a

238 TCR stimulation is impaired in subjects with relapsing-remitting multiple sclerosis (RRMS) because of

239 umab is a newly licensed treatment of active relapsing-remitting multiple sclerosis (RRMS) in Europe,

240 e total circulating exosome transcriptome in relapsing-remitting multiple sclerosis (RRMS) patients a

241 e previously showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients e

242 Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients w

243 le SclerOsis (ALLEGRO), a phase III study in relapsing-remitting multiple sclerosis (RRMS), oral laqu

244 cetate (GA) are widely used in patients with relapsing-remitting multiple sclerosis (RRMS).

245 factors with long-term clinical outcomes in relapsing-remitting multiple sclerosis (RRMS).

246 odulator, for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

247 Participants were patients with relapsing-remitting multiple sclerosis 18 to 55 years ol

248 l trials (Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis [AFFIRM], Safety

249 ion With Interferon Beta-1a in Patients With Relapsing-Remitting Multiple Sclerosis [SENTINEL], and I

250 atents for the first approved treatments for relapsing-remitting multiple sclerosis are expiring, cre

251 their effects on disability in patients with relapsing-remitting multiple sclerosis are maintained an

252 ratio values in the outer cord were lower in relapsing-remitting multiple sclerosis compared with cli

253 DMTs by comparing a cohort of patients with relapsing-remitting multiple sclerosis enrolled in the U

254 ed cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing rela

255 trial, patients aged 18-60 years with active relapsing-remitting multiple sclerosis from 84 centres i

256 d data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase a

257 at have regulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no

258 nd extra-cellular sodium concentration in 19 relapsing-remitting multiple sclerosis patients and 17 h

259 nd 4-6 and 18-26 mo Tecfidera-treated stable relapsing-remitting multiple sclerosis patients using mu

260 312 on MRI Lesion Given Once Daily) Study in relapsing-remitting multiple sclerosis provides evidence

261 , phase 3 study involving 1841 patients with relapsing-remitting multiple sclerosis to compare dacliz

262 olimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to

263 Women aged 18-50 years with relapsing-remitting multiple sclerosis were randomly ass

264 ggestive of CNS demyelination and typical of relapsing-remitting multiple sclerosis, a complete neuro

265 Eligible patients were aged 18-55 years, had relapsing-remitting multiple sclerosis, and had complete

266 ears old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive

267 than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy

268 Among patients with relapsing-remitting multiple sclerosis, daclizumab HYP s

269 lusion criteria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one

270 As treatment for relapsing-remitting multiple sclerosis, glatiramer aceta

271 ns is the underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accu

272 ligible patients-those aged 18-55 years with relapsing-remitting multiple sclerosis-to receive fingol

273 rferon beta-1a (IFNbeta-1a) in patients with relapsing-remitting multiple sclerosis.

274 d for the treatment of people suffering from relapsing-remitting multiple sclerosis.

275 the first mAb approved for the treatment of relapsing-remitting multiple sclerosis.

276 milar effects on annualised relapse rates in relapsing-remitting multiple sclerosis.

277 lockade on Treg homeostasis in patients with relapsing-remitting multiple sclerosis.

278 erapy approved for treatment of relapsing or relapsing-remitting multiple sclerosis.

279 rug Administration approved for treatment of relapsing-remitting multiple sclerosis.

280 negative prognostic factor in patients with relapsing-remitting multiple sclerosis.

281 ation due to adverse events in patients with relapsing-remitting multiple sclerosis?

282 cretion in urine samples from a cohort of 70 relapsing-remitting patients with MS who were followed f

283 ent disease-modifying agents for its initial relapsing-remitting phase, these therapies show limited

284 he article presents a case of a patient with relapsing-remitting severe BBE.

285 ohort of 18 MS patients (9 progressive and 9 relapsing-remitting) was compared to healthy controls an

286 icipants included 36 individuals with MS (30 relapsing-remitting, 6 secondary or primary progressive)

287 of Gli1 improves the functional outcome in a relapsing/remitting model of experimental autoimmune enc

288 Atopic dermatitis (AD) is a chronic relapsing skin disease prevalent in 1% to 3% of adults i

289 Herpes simplex virus (HSV) causes acute and relapsing symptoms characterized by ulcerative lesions.

290 In a phase 3 study of patients with relapsing symptoms of IBS-D, repeat rifaximin treatment

291 women, and its outcome is characterized by a relapsing tendency.

292 Relapsing to drug abuse despite periods of abstinence an

293 ponse can safely cease their therapy without relapsing (treatment free remission [TFR]).

294 rolled trial, adults with newly diagnosed or relapsing vasculitis received placebo plus prednisone st

295 abolites most altered in rats with active or relapsing vasculitis were trimethylamine N-oxide (TMAO),

296 Comparison of outcomes in patients with a relapsing vs nonrelapsing disease also were analyzed.

297 The percentage relapsing was not statistically significant (P = 0.33) b

298 Overall, the estimated proportion relapsing within 12 months was 27.8% (95% confidence int

299 isease and/or poor cytogenetics at diagnosis relapsing within the first 2 years from ASCT should be c

300 ses, but with ultimate recovery (22.5%); and relapsing without recovery (14.7%).